Acute Myeloid Leukemia | Topics

Frequent targetable mutations in patients with extramedullary acute myeloid leukemia lends credence to the use of next-generation sequencing to determine the optimal targeted therapy approach.

In patients with acute myeloid leukemia receiving venetoclax, tumor lysis syndrome was uncommon; patients at high risk should be admitted for venetoclax dosing ramp-up.

The FDA has placed a full clinical hold on a phase 1 trial assessing FHD-286 as a potential treatment for patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome due to concerns around suspected cases of fatal differentiation syndrome that may be associated with the agent.

Adult patients with acute myeloid leukemia who are not eligible for treatment with standard induction chemotherapy may benefit from treatment with decitabine and cedazuridine, the marketing authorization application for which was accepted by the European Medicines Agency.

Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.

Although European Leukemia Net 2017 Risk Stratification was ineffective for predicting outcomes following allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia, pre-transplant Wilms tumor gene 1 expression and FLT3-ITD mutation demonstrated promising predictive ability.

Black adolescent young adult patients with acute myeloid leukemia appeared to have inferior outcomes compared with White patients.

Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.

The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.